SPDR S&P Biotech ETF Newsroom

Cracking The Code: Understanding Analyst Reviews For Incyte

Benzinga04:00

Gilead, Vertex Initiated as New Big Biotech Buys at Citi

Seeking Alpha03:26

Incyte Analyst Ratings

Benzinga01:05 · Ratings

InspiroGene by McKesson Partners With Vertex To Expand Distribution Of CASGEVY, The First FDA-Approved CRISPR Gene-Editing Therapy For Sickle Cell Disease And Β-Thalassemia

BenzingaNov 14 22:04

Gilead Sciences Analyst Ratings

BenzingaNov 14 20:58 · Ratings

Vertex Pharmaceuticals Analyst Ratings

BenzingaNov 14 20:51 · Ratings

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

BenzingaNov 14 05:05

Natera Analysts Increase Their Forecasts Following Upbeat Results

BenzingaNov 14 02:38

10 Health Care Stocks With Whale Alerts In Today's Session

BenzingaNov 14 01:35

Paymentus Posts Better-Than-Expected Earnings, Joins Dave, Honest Company, Natera, CAVA Group And Other Big Stocks Moving Higher On Wednesday

BenzingaNov 13 23:19

Starbucks To $77? Here Are 10 Top Analyst Forecasts For Wednesday

BenzingaNov 13 20:45

Market-Moving News for November 13th

BenzingaNov 13 20:25

Baird Maintains Outperform on Natera, Raises Price Target to $160

BenzingaNov 13 20:23 · Ratings

Natera Analyst Ratings

BenzingaNov 13 20:22 · Ratings

Viking Therapeutics To Present Data From Phase 2b VOYAGE Study Of VK2809 In Patients With Biopsy-Confirmed NASH/MASH At 75th Liver Meeting 2024

BenzingaNov 13 05:54

Natera Sees FY24 SG&A $775M-$825M; R&D $375M-$400M' Net Cash Inflows $50M-$75M.

BenzingaNov 13 05:17

Natera Sees FY24 Revenue $1.61B-$1.64B Vs $1.518B Est

BenzingaNov 13 05:16

Natera Q3 2024 GAAP EPS $(0.26) Beats $(0.58) Estimate, Sales $439.800M Beat $361.450M Estimate

BenzingaNov 13 05:13

ARKK's Holdings Ranked by SA Quant Grades

Seeking AlphaNov 13 03:21

AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio

BenzingaNov 13 02:52